1 张庆荣,李德新.支气管哮喘与气道炎症和支气管高反应性.国外医学呼吸系统分册,1996;16(2):75
2 Holgate S T.Mediator and cytokin mechanisms in asthma.Thor ax,1993;48:103
3 张伟.哮喘气道炎症的非创伤性检测.国外医学呼吸系统分册,1997;17(3):113
4 Ohnishi T,Kita H,Weiler D,et a l.IL-5 is the pre-dominant eosinophil-active cytkoine in the antigen-induced pulmonary late-phase reaction.Am Rev Res Dis,1993;147:901
5 Echazarreta AL,Gomez FP,Ribas J,et al.Effects of inhaled furosemide on platelet-actvating factor chal-lenge in mild asthma.Eur Respir J,1999;1 4(3):616
6 周兆山,张明理,主编.支气管哮喘临床新对策.第1版.北京:中国中医药出版社,1998:163
7 李明华,殷凯生,朱栓立,主编.哮喘病学.第1版.北京:人民卫生出版社,1998:257
8 赖克方,王长征,郭先健.糖皮质激素对嗜酸粒细胞的作用.国外医学呼吸系统分册,1998;18(4):195
9 阎锡新.吸入类固醇对哮喘的疗效与副作用.国外医学呼吸系统分册,1994;14(2):67
10 刘长恩,乔华,马俊义.吸入糖皮质激素的全身副作用.国外医学呼吸系统分册,1998;18(4):198
11 Brogden RN,Sorkin EM.Nedocromil sodium:An updated review of its pharmacological properties and therapeutic efficacy in asthma.Drugs,1993;45:693
12 Lipworth BJ.Leukotriene-receptor antagonists.Lancet,1999;353(9146):57
13 Roberts JA,Bradding P,Britten KM,et al.The long-acting be ta2-agonist salmeterol xinafoate:effects on airway inflammation inasthma.Eur Respir J,1999;14(2):275
14 Vevini M.Comparison of the bronchodilatation of inhaled short-acting and long-acting bet a2-agonist in asthma childen.Clin Drug Invest,1998;16(1):19
15 Grutters JC,Brinkman L,Aslander M M,et al.Asth-ma therapy modulates priming-associated blood eosinophil responsiveness in allergic asthmatics.Eur Respir J,1999;14(4):915
16 张齐武.长期吸入β2受体激动剂的潜在危险.国外医学呼吸系统分册,1997;17(2):75
17 谢晓宾.茶碱的研究现状.北京医学,1994;(4):227
18 Frew AJ,Holgate S T.Clinical pharmacologyof asthma.Drugs,1993;46(5):847
19 胡红,刘又宁.选择性磷酸二酯酶抑制剂在支气管哮喘治疗中的作用.国外医学呼吸系统分册,1996;16(1):4
20 李春生.支气管哮喘中医药治疗研究进展.中国中西医结合杂志,1995;15(7):426
21 沈自伊.支气管哮喘的中西医结合防与治.中国中西医结合杂志,1993;13(5):296 |
